University Of Kansas is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
|
| 🏛️ |
| Location | Lawrence, Kansas, USA |
|---|
| Type | Public Research University |
|---|
| Founded | 1866 |
|---|
| Website | https://www.ku.edu |
|---|
| Medical Center | Kansas City, Kansas |
|---|
The University of Kansas (KU) is the state's flagship research university with a strong commitment to neuroscience and neurodegeneration research. The University of Kansas Medical Center in Kansas City houses the Alzheimer's Disease Center and the Frontiers in Alzheimer's Disease Research program, making it a major hub for neurodegenerative disease research in the Midwest. KU researchers focus on understanding disease mechanisms, identifying biomarkers, and developing novel therapeutics for Alzheimer's disease, Parkinson's disease, and related disorders.
Founded in 1866, the University of Kansas has grown to become a major research institution. The KU Medical Center was established in 1905, and the Alzheimer's Disease Center was designated by the National Institute on Aging in 2014. The center has since become a regional leader in Alzheimer's research, clinical trials, and patient care.
KU researchers focus on multiple aspects of neurodegeneration:
- Amyloid Biology: Studies on APP processing, Aβ aggregation mechanisms, and therapeutic antibodies
- Tau Pathology: Investigation of tau phosphorylation, spread, and therapeutic targeting
- Biomarkers: Development of CSF and blood biomarkers for early detection
- Clinical Trials: Participation in multicenter trials for disease-modifying therapies
- Cellular and molecular mechanisms of brain aging
- Synaptic dysfunction in aging
- Metabolic changes in aged neurons
- Cognitive decline prevention strategies
- Novel therapeutic compounds for neurodegenerative diseases
- High-throughput screening for disease-modifying drugs
- Repurposing existing drugs for new indications
- Target validation and mechanism of action studies
¶ Parkinson's and Movement Disorders
- Alpha-synuclein biology and therapeutics
- Neuroprotection strategies
- Lewy body disease research
- Deep brain stimulation outcomes
| Disease |
Research Focus |
| Alzheimer's Disease |
Amyloid therapeutics, biomarkers, clinical trials |
| Parkinson's Disease |
Neuroprotection, Lewy body disease, alpha-synuclein |
| Vascular Cognitive Impairment |
Cerebrovascular contributions to dementia |
| TBI-Related Neurodegeneration |
Chronic effects of traumatic brain injury |
| Lewy Body Dementia |
DLB clinical and basic research |
The NIA-funded Alzheimer's Disease Center at KU Medical Center conducts:
- Memory assessments and clinical evaluations
- Brain imaging studies (MRI, PET)
- Biomarker research
- Clinical trials for new treatments
- Caregiver support and education programs
State-of-the-art facilities for:
- High-throughput compound screening
- In vitro models of neurodegeneration
- Target identification and validation
- Preclinical drug development
Advanced neuroimaging capabilities including:
- 3T and 7T MRI scanners
- PET imaging for amyloid and tau
- Functional MRI for cognitive studies
- Diffusion tensor imaging for white matter
¶ Landon Center on Aging
Research and clinical programs focused on:
- Age-related diseases
- Geriatric medicine
- Cognitive health in aging
- Caregiver support programs
- Memory Disorders Clinic: Comprehensive evaluation and treatment for memory disorders
- Movement Disorders Clinic: Parkinson's disease and related conditions
- Clinical Trials Unit: Active enrollment in therapeutic trials
- Caregiver Support Program: Education and resources for families
- PhD programs in Neuroscience, Pharmacology, and Aging Biology
- MD/PhD combined degree programs
- Postdoctoral training in neurodegeneration research
- Clinical fellowship programs in geriatric medicine
- Summer undergraduate research internships
The University of Kansas serves as the primary research hub for neurodegenerative disease in the Midwest:
- Patient Care: Providing cutting-edge diagnostic and treatment services to Kansas and surrounding states
- Clinical Trials: Giving patients access to the latest experimental therapies
- Education: Training the next generation of neuroscientists and clinicians
- Community Outreach: Educating the public about brain health and disease prevention
KU collaborates with:
- National Institute on Aging (NIA)
- Alzheimer's Association
- Pharmaceutical companies (Biogen, Eli Lilly, Janssen)
- Other Alzheimer's Disease Research Centers
- State of Kansas health agencies
The study of University Of Kansas has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- University of Kansas Medical Center. (2024). Alzheimer's Disease Center. https://www.kumc.edu/
- NIH National Institute on Aging. (2024). Alzheimer's Disease Research Centers.
- KU Research. (2024). Neuroscience and Neurodegeneration Programs.
- PubMed-indexed publications from KU researchers in Alzheimer's, Parkinson's, and related fields.